We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





ECCMID 2022 Takes Place for the First Time as Hybrid Event Both Onsite and Online

By LabMedica International staff writers
Posted on 22 Apr 2022

The 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) took place in Lisbon, Portugal from April 23-26 – for the first time as a hybrid event both onsite and online. More...

ECCMID is the world’s premier clinical microbiology & infectious diseases event organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program.

ECCMID 2022 offered excellent opportunities to corporate partners to showcase their latest findings, share their experiences and knowledge and demonstrate practical techniques and guidance. A comprehensive program covered the entire range of ECCMID topics with high-level speakers. Participants had the opportunity to meet researchers from many parts of the world to discuss methods, results and the impact on clinical and laboratory practice. Additionally, young professionals had the opportunity to discuss their ideas and projects with renowned experts in a variety of interactive sessions that also provided networking opportunities.

This year’s ECCMID once again featured pipeline corners where innovative companies and research groups were offered a platform to present their early-stage antimicrobial therapies, diagnostic products in development, and research funding opportunities to a wider audience. This was complemented by scientific content co-developed with the industry such as the integrated symposia.

Other new features from ECCMID 2021 that returned this year were the Keynote Fireplace sessions where ECCMID keynote speakers met with a small group of participants to enter a more in-depth discussion on their keynote lecture. Additionally, the infectious disease-themed Escape Room was reprised and updated as an immersive interactive addition.

Related Links:
ESCMID 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Chromogenic Culture System
InTray™ COLOREX™ ECC
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.